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Abstract
Diagnosis of a child with Duchenne or Becker muscular dystrophy (DBMD) may impact future 
maternal reproductive choice; however, little is known about the reproductive patterns of mothers 
with a male child diagnosed with DBMD. Using population-based surveillance data collected by 
the muscular dystrophy surveillance, tracking, and research network, the proportion of mothers 
who conceived and delivered a live birth following the diagnosis of DBMD in an affected male 
child and factors associated with such reproductive choice were identified. To accomplish this, 
maternal demographic data were linked to birth certificate data to construct the reproductive 
history for 239 mothers. Univariable and bivariable analyses were conducted to determine the 
proportion of mothers delivering a live birth and associated factors. By the time of the current 
study, 96 (40.2%) of the 239 mothers had at least one live birth following delivery of their oldest 
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affected male child; 53 (22.2%) of these mothers had a live birth before and 43 (18.0%) had a live 
birth after DBMD diagnosis of a male child. Mothers with a live birth after diagnosis were 
significantly younger at diagnosis of the oldest affected male child (26.2 ± 4.2 years vs. 31.5 ± 5.5 
years), and were less likely to be white non-Hispanic compared to those with no live birth after 
diagnosis. These results suggest that about one in five mothers deliver a live birth subsequent to 
DBMD diagnosis in a male child. Maternal age and race/ethnicity were associated with this 
reproductive choice.
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INTRODUCTION
Duchenne (OMIM 310200) and Becker (OMIM 300376) muscular dystrophies (DBMD) are 
X-linked progressive muscle conditions, affecting approximately 1.3–1.8/10,000 males 
[Centers for Disease Control and Prevention (CDC), 2009]. The primary mode of genetic 
transmission for these conditions is due to the mother being a carrier of an altered dystrophin 
gene, and the remainder is due to a new mutation in the affected son; thus, mothers of males 
with DBMD may or may not have a family history of these conditions. Early signs and 
symptoms of DBMD include difficulty walking, running, or climbing stairs, and progressive 
muscle weakness. Currently, no cure exists for DBMD. Management includes use of 
corticosteroids to slow disease progression and treatment of associated cardiac, pulmonary, 
and skeletal complications [Bushby et al., 2010a,b].
Diagnosis of DBMD in a child may influence a mother’s reproductive choices; however, 
only two published investigations have examined the reproductive patterns of mothers 
following the diagnosis of Duchenne muscular dystrophy (DMD) in a male child. One 
investigation, a pilot study of eight mothers of males diagnosed with DMD by newborn 
screening and three female relatives at high risk of being carriers, found that four (50%) of 
the eight mothers with an affected male child had one or more subsequent pregnancies 
[Hildes et al., 1993]. The second investigation, a pilot study of 20 families with an affected 
male child with DMD identified by newborn screening, found that four (20%) families chose 
not to have another pregnancy after the diagnosis and 11 (55%) opted to delay additional 
pregnancies [Parsons et al., 2002]. Additional data suggest that males born to women with a 
prior knowledge of DMD family history are often diagnosed at an earlier age [Gardner-
Medwin et al., 1978; Smith et al., 1989] compared to males born to women with no such 
knowledge [Ciafaloni et al., 2009]. Given this preliminary evidence, data from the 
population-based muscular dystrophy surveillance, tracking, and research network (MD 
STARnet) were used to examine reproductive patterns among mothers of males diagnosed 
with DBMD. Specifically, the proportion of mothers who conceived and delivered a live 
birth following the diagnosis of DBMD in an affected male child was calculated, and factors 
associated with such reproductive choice were examined.
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MATERIALS AND METHODS
Study Design and Setting
A retrospective cohort study using data collected by the MD STARnet was conducted. The 
MD STARnet is a multisite project established in 2002 by the Centers for Disease Control 
and Prevention (CDC) to conduct population-based surveillance for individuals with DBMD 
born on or after January 1, 1982, and who resided in an MD STARnet site. Initially, the MD 
STARnet was comprised of four sites, Arizona (AZ), Colorado (CO), Iowa (IA), and western 
New York State (NY). Subsequently, activities were expanded to include Georgia (GA) in 
2006 and Hawaii (HI) in 2008. Details of this project have been described elsewhere [Miller 
et al., 2006].
Study Population and Sample
The population for this study was comprised of mothers of males with a characteristic 
clinical course for DBMD defined by an elevated creatine kinase (CK) level, and either a 
dystrophin analysis that showed apathogenic abnormality, amuscle biopsy that showed 
abnormal dystrophin by immunostaining or Western blot, or a documented family history of 
an X-linked muscular dystrophy [Mathews et al., 2010]. Surveillance data collected through 
2008 were used for this study, and included data on 536 mothers from AZ, CO, GA, IA, and 
NY with affected males born from 1982 to 2006; surveillance had not yet commenced in HI. 
Of the 536 mothers, 218 from CO and GA were excluded because birth certificate (BC) data 
were not available for linkage, and seven mothers from AZ, IA, and NY were excluded as 
the oldest affected male was adopted and BC data on the biological mothers were not 
available leaving 311 eligible mothers for data linkage and analyses.
Data Sources and Variables
Surveillance data were collected from medical records (MRs) and the BC, where available, 
for an affected male child, and included sociodemographics, birth history, clinical signs and 
symptoms, diagnostic tests, mobility, rehabilitation, co-morbidities (pulmonary, cardiac, 
skeletal, and psychosocial), and family history of DBMD. To construct maternal 
reproductive history subsequent to the birth of the oldest affected male child, MD STARnet 
data were linked to state BCs, through 2009. From the BC linkage, data were collected on 
birth date and sex of each subsequent live birth and maternal parity. A combination of 
deterministic and probabilistic approaches was used to match maternal MD STARnet and 
BC data [Romitti et al., 2010]. Institutional review boards from AZ, IA, and NY approved 
the study.
Independent variables examined to describe the study sample were: age (years) of the oldest 
affected male child at first creatine kinase (CK) testing (used as a proxy for DBMD 
diagnosis); maternal age (years), race/ethnicity (white non-Hispanic, Hispanic, black non-
Hispanic, Native American, Asian or Pacific Islander, and other), and education (less than 
high school, high school, some college and college degree or higher); parity (0, 1 and 2 or 
more pregnancies); knowledge of DBMD family history (known history, no known history, 
and undetermined history) at delivery of her oldest affected male child; carrier status 
(carrier, suspected carrier, non-carrier, and unknown); and receipt of genetic counseling 
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(recommended, received, and unknown) at any time point prior to completion of surveillance 
data collection in 2008. To define knowledge of family history, MR and pedigree data were 
used to determine if the mother had a “known history” of other affected maternal relatives 
(e.g., an uncle, cousin, grandfather, or great uncle) diagnosed with DBMD, “no known 
history” of other affected family members, or “undetermined history” if data were 
insufficient to determine prior knowledge of DBMD family history. Carrier status was 
defined from pedigree data, maternal CK levels, and when available, DNA test results. A 
mother was classified as a “carrier” if the pedigree indicated she was an obligate carrier or if 
genetic testing detected a DBMD mutation; as a “suspected carrier” if the pedigree showed 
possible carrier status, and/or the mother had an elevated CK but genetic testing was 
unavailable; as a “non-carrier” if genetic testing indicated no dystrophin mutation in the 
mother; or as an “unknown carrier” if insufficient data were available to determine carrier 
status. Receipt of genetic counseling was defined from MR data, and was classified as 
“recommended” if counseling was recommended but there was no indication to suggest that 
it was completed; as “received” if counseling was completed; or as “unknown” if there were 
no data to indicate if counseling was recommended or received. Independent variables 
compared between mothers who did and did not deliver a live birth after diagnosis of their 
oldest affected male child included each variable listed above, except that maternal age was 
at the time of DBMD diagnosis of the male child, and parity was categorized (1, 2 and 3 or 
more pregnancies) to include, at a minimum, the delivery of the oldest affected male child.
A mother who conceived and delivered one or more live birth(s) after diagnosis of her oldest 
affected male child was categorized as having a live birth after diagnosis, and a mother who 
did not have a live birth or who had a live birth before diagnosis of her oldest affected male 
child was categorized as having no live birth after diagnosis. To determine if a mother had a 
live birth after diagnosis of her oldest affected male child, age at first CK for the child was 
compared to the birth intervals of each delivery that occurred after the birth of the child. To 
allow fora 3-month preconception interval and a term pregnancy, 1 year was subtracted from 
the birth interval of each subsequent live birth. If the birth interval was larger than the 
interval from birth to age at first CK, then a mother was classified as having a live birth after 
diagnosis of her oldest affected male child.
Data Analysis
Univariable and bivariable analyses were conducted to estimate frequencies and percentages 
for categorical variables and to estimate means, standard deviations (SDs), and ranges for 
continuous variables. The chi-square or Fisher exact tests, as appropriate, were calculated to 
assess significant differences (P < 0.05) for categorical variables, and t-tests were calculated 
to assess significant differences for continuous variables. Because of small numbers, 
education categories (less than high school, high school, some college, and bachelor’s 
degree or higher) were collapsed into high school or less, some college, and college degree 
or higher. Similarly, race/ethnicity categories (white non-Hispanic, Hispanic, black non-
Hispanic, Native American, Asian or Pacific Islander, and other) were collapsed into white 
non-Hispanic and all other race/ethnicity. All analyses were conducted using Statistical 
Analysis Software (SAS) version 9.2, Cary, North Carolina, U.S.
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RESULTS
Of the 311 mothers from AZ, IA, and NY identified for record linkage, 72 mothers were 
excluded from analyses producing a final analytic sample of 239 mothers. Mothers were 
excluded if: the oldest affected male child was born before 1982 (n = 4), was not identified 
in the 2008 surveillance data (n = 1), or had an unknown age at DBMD diagnosis (n = 12); 
BC data were missing (n = 43); or knowledge of DBMD family history at delivery of their 
oldest affected male child was undetermined (n = 12). Mothers included in the final analyses 
and those excluded differed by race/ethnicity, carrier status, and receipt of genetic 
counseling (Table I).
At the time of the current study, 96 (40.2%) of the 239 mothers had delivered one or more 
live birth(s) following the birth of their oldest affected male child. Fifty-three (22.2%) 
mothers delivered 63 live births (28 females and 35 males) before diagnosis of their oldest 
affected male child; 12 of the 35 males were identified by the MD STARnet as having 
DBMD. The remaining 43 (18.0%) mothers delivered 53 live births (20 females and 33 
males) after diagnosis of their oldest affected male child with 12 of the 33 males identified 
by the MD STARnet. To evaluate potential differences in the opportunity to conceive 
between mothers who had no live birth and mothers who either had a live birth before or 
after diagnosis of their oldest affected male child, the intervals between maternal age at BC 
request and maternal ages at delivery and at diagnosis of their oldest affected male child 
were compared. No statistically significant differences were found (data not shown).
Table II shows maternal factors associated with having a live birth following the diagnosis of 
DBMD in an affected male child. Mothers who had a live birth after diagnosis of their oldest 
affected male child were more likely to be younger and less likely to be white non-Hispanic 
compared to mothers who did not have a live birth after diagnosis. Mothers in each group 
tended not to differ by: education and knowledge of DBMD family history at time of 
delivery of the oldest affected male child; parity at diagnosis of the oldest affected male 
child; or carrier status and receipt of genetic counseling at any time point prior to 
surveillance data collection in 2008.
DISCUSSION
Approximately 18% of mothers in this study had a live birth following the diagnosis of their 
oldest affected male child, which is lower than the 50% reported in one previously published 
pilot study [Hildes et al., 1993], but similar to the 25% reported in another pilot study whose 
reproductive choices were not affected by such diagnosis [Parsons et al., 2002]. Differences 
in study design, sample size, and study populations may explain the variability in findings. 
The two previous studies [Hildes et al., 1993; Parsons et al., 2002] were pilot projects that 
used samples sizes of 8 and 20 mothers, respectively, identified through newborn screening 
for DBMD, whereas the current study was based on a large sample of mothers of male 
children with DBMD identified through a population-based surveillance approach. Mothers 
of affected male children identified through newborn screening may be more likely to have a 
second child before their affected male child begins to show signs of the disease. Observing 
the progression of DBMD in their own child may have a greater effect on the mother’s 
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future reproductive choices compared to knowing that there may be a chance that a future 
child may inherit the disease. The fact that knowledge of a positive family history did not 
differ in the current study between mothers who did and did not have another child 
following a diagnosis in an older child is consistent with this interpretation. As such, these 
mothers may have opted not to have another child. Other reasons that may explain the 
observed differences between this study and previous studies may be related to a general 
population decline in birth rates over time [Hamilton and Ventura, 2006] or use of 
reproductive technologies such as prenatal testing [Raymond et al., 2010], which may lead 
to termination of pregnancies with an affected fetus. The retrospective design of the current 
study did not permit the latter factor to be fully assessed.
Factors associated with reproductive decisions for mothers at risk of having a child with a 
genetic disorder have been examined previously. Published findings suggest that a mother’s 
desired number of children [Hildes et al., 1993], receipt of genetic counseling [Abramovsky 
et al., 1980; Rona et al., 1994; Eggers et al., 1999; Meldrum et al., 2007], perception of 
disease risk [Hutton and Thompson, 1976; Abramovsky et al., 1980; Wertz et al., 1984], 
concerns about the effects of an affected child on one’s social and personal life and problems 
caring for the child [Wertz et al., 1984; Frets et al., 1991], and disapproval of relatives [Frets 
et al., 1991], may play a role in decisions about reproduction.
In the current study, mothers’ age at diagnosis of her oldest affected male child and her race/
ethnicity were each associated with having a live birth following the diagnosis. The observed 
association of younger mothers having an increased tendency to have additional children 
could be a reflection of the general population trend of younger mothers having more births 
compared to older mothers [Hamilton et al., 2006]. Fertility rates are also higher in younger 
mothers [American Society of Reproductive Medicine, 2008]. Conversely, younger mothers 
may feel as though they have sufficient resources, both internally and externally, to have 
another child regardless of diagnosis. Cultural and/or religious differences with respect to 
reproduction may explain the findings related to race/ethnicity [Brotto et al., 2008; 
Maternowska et al., 2010]. Family pressures to have more children and cultural norms 
regarding family planning have been reported to influence reproductive choice [Godley, 
2001; Oladeji, 2008]. Unfortunately, these differences could not be fully examined using the 
available MD STARnet data.
Parity at diagnosis of the oldest affected male was not associated with having a live birth 
after DBMD diagnosis in an older child. A trend towards significance was found for the 
association between carrier status and subsequent children. Mothers of confirmed or obligate 
carrier status tended to have additional children whereas mothers of unknown carrier status 
were less likely to have additional children after diagnosis of the oldest male. Reports on the 
effect of carrier status for heritable disease on reproductive choices of mothers have been 
inconsistent with associations reported in some [Zatz, 1983; Meldrum et al., 2007], but not 
all [Eggers et al., 1999; Knol et al., 2011], studies. Although the findings in this study appear 
to suggest that knowing carrier status may increase the likelihood of having subsequent 
children, the approach to determining carrier status makes it difficult to attribute causative 
associations with these data. Specifically, MRs were reviewed throughout the entire 
surveillance period; thus, carrier status may not have been determined by the time of the 
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subsequent pregnancy. Furthermore, pregnancies subsequent to the oldest affected male 
could increase the certainty of the mother’s carrier status (e.g., a second affected male 
prompted genetic testing). If the mother did not have any additional children, then carrier 
status may be more likely to be classified as unknown due to the absence of additional 
confirmatory information.
Although additional studies have reported that receipt of genetic counseling is associated 
with reproductive choice [Abramovsky et al., 1980; Zatz, 1983; Rona et al., 1994], no such 
association was found in the current study. As with carrier status, it is important to note that 
the findings related to genetic counseling in the current study are limited because of the 
inability to determine when counseling occurred or the type of information provided in 
counseling sessions from the MD STARnet data. Additionally, information on perception of 
disease risk, concerns about the effects of an affected child on one’s social and personal life, 
problems caring for the child, and approval or disapproval of relatives were not available for 
analyses in the MD STARnet data.
In summary, findings showed that the reproductive patterns for most women studied did not 
change after a first diagnosis of DBMD in an affected male child, and may not differ much 
from those of women in the general US population. The current study is limited by its 
retrospective design, which did not allow assessment of changes in genetic testing and 
counseling or prenatal testing that have taken place over the years. Also, the use of 
secondary data (MRs and BCs) increased the potential for missing or incomplete data, which 
limited available sample size for analysis [Kirby and Malnory, 1999]. Additionally, 
stillbirths and terminations were not examined. Nonetheless, the current study is one of the 
few studies using a population-based sample, which make the findings more generalizable. 
Further, the study linked MD STARnet and BC data, which provided a more complete 
ascertainment of maternal reproductive history. Future studies should examine more fully 
the impact of genetic counseling on mothers’ future reproductive choices.
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